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CYCLIC VOMITING SYNDROME: A RETROSPECTIVE PATIENT CHART 
REVIEW 
KATHARINE WEBER 
ABSTRACT 
Purpose: We aim to characterize a large cohort of CVS patients seen at MGH in order to 
better understand this disorder. In addition, as CVS patients are known to have a higher 
cannabis use than those with other functional disorders, characteristics specific to CVS 
marijuana user patients have yet to be determined. Therefore, we aim to determine the 
variables that are patient specific predictors of cannabis use in CVS. 
Methods: All patients with a CVS diagnosis were seen at our facility as inpatient, 
outpatient or in the emergency department and medical record numbers were identified 
via Research Patient Data Registry (RPDR) query search tool. From the medical records, 
we verified a diagnosis of CVS based on Rome III criteria and collected information on 
demographics, co-morbidities, health care utilization and substance abuse history over a 
16 year time period (1997-2013). We then proposed patient specific predictor variables of 
marijuana use based on our experience with CVS patients and incorporated these 
variables into a model for predicting marijuana use. We used this model to examine the 
effect of patient characteristics on marijuana use via logistic regression with estimation of 
odds ratio and 95% confidence ratio. 
Results:  A total of 91 CVS patients were obtained, 67% of which were male with a 
mean age of 28 years old, average age of first attack of 20.2 years and employment or full 
time student status in 62% of patients. Psychiatric conditions were present in 73% of 
	  	   vii 
individuals with anxiety present in 50% and depression in 47%. The presence of a 
chronic pain syndrome was found in 40%. Marijuana use was present in 76% of our 
cohort, daily alcohol use 53%, and narcotic use 27%. Men with CVS were at significantly 
greater risk for marijuana use compared to women (OR .23, 95% CI .07-.77) as well as 
daily alcohol use (OR 5.26, 95% CI 1.469-18.828). Individuals with a chronic pain 
syndrome were at significantly lower risk for cannabis use (OR .15, 95% CI .039-.575) 
and psychiatric illness, age and narcotic use were found not to be associated with 
marijuana use. On average, individuals presented to the ED 1.6 times/year with one 
patient having a high of 208 ED visits/year. Of those that presented more than once 
during the time period in study there was a median interval between visits of 103.6 days.  
Conclusion: We found that CVS patients had significant psychiatric co-morbidities, 
chronic pain syndromes, and history of substance abuse. We found male gender and 
alcohol use to be two variables that were predictors of marijuana use in the CVS 
population while the presence of a chronic pain syndrome decreased the likelihood of 
marijuana use. The significant employment rate and full time student status of our cohort 
suggests a higher degree of functionality. Further prospective studies are needed to 
determine the role of marijuana use in the CVS population in terms of quality of life, 
health care utilization, and severity of disease.  
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INTRODUCTION 
 
Cyclic Vomiting Syndrome 
Cyclic Vomiting Syndrome (CVS) is a rare disorder characterized by episodic 
bouts of severe nausea and vomiting with periods of wellness between attacks (Hejazi & 
McCallum, 2011).  In 1882, Samuel Gee first described CVS in English literature with a 
report of the illness in nine children (Abell et al., 2008; Hejazi & McCallum, 2011). 
Since the initial description, CVS is now increasingly being recognized in not only 
pediatric populations but in adults as well. Although the exact prevalence is not known in 
adults, it is estimated to effect anywhere from .04-2% of the pediatric population (Hejazi 
& McCallum, 2011). Information on the demographics that CVS affects is not yet 
definitive, however CVS has been noted in all races with whites being affected to a 
greater extent than other races (Pareek, Fleisher, & Abell, 2007). There appears to be a 
higher incidence of CVS among women than men as well (Tonore, Spree, & Abell, 
2013).  
Pathophysiology Theories 
There have been abnormalities noted in CVS patients and theories proposed to 
explain the mechanisms of dysfunction, however CVS remains a disorder of unknown 
etiology. Hormonal abnormalities, autonomic nervous system (ANS) dysfunction, 
mitochondrial dysfunction, and abnormal Gastric Emptying Time (GET) have been 
observed in some CVS patients and theories have been proposed surrounding these 
findings. 
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Hormonal Abnormalities 
Corticotrophin releasing factor (CRF) is hypothesized to contribute to the 
initiation of vomiting during a CVS episode. One of the main functions of CRF is to 
activate the hyophyseal-pituitary-adrenal axis (HPA) and the stress response via 
stimulation of adrenocorticotropic hormone (ACTH) and cortisol release (Abell et al., 
2008).  Supporting this is a finding from one group of elevation of ACTH, cortisol and 
catecholamine levels prior to the onset of a CVS episode (Pareek et al., 2007). CRF 
release activated by either physical or psychological stress and it’s downstream effectors 
also subsequently causes dysregulation of gut motility (Hejazi & McCallum, 2011).  One 
of the effects of CRF is the inhibition of gastric motor activity, which can then help to 
precipitate nausea and vomiting (Pareek et al., 2007). In one study, per parent report, 
various types of stress such as infections, psychological stress or excitement precedes and 
triggers a CVS episode in up to 76% of pediatric patients (Li & Misiewicz, 2003). In this 
study, parents reported that the stressor was more likely to be associated with positive 
events such as birthdays, vacations, holidays or family gatherings rather than negative 
stressors (Li & Misiewicz, 2003). Furthermore, CVS episode onset often occurs late at 
night or in the early hours of the morning, perhaps corresponding to when the secretion of 
CRF takes place, between 1 AM and peaking at 6 AM (Pareek et al., 2007).  
The hormone ghrelin has also been shown to be at abnormal levels in a study 
involving adult CVS patients. Ghrelin, released during a meal and produced by the 
gastric mucosa, decreases gastric emptying time (GET) (Hejazi, Lavenbarg, & 
McCallum, n.d.). This hormone is theorized to be involved with rapid gastric emptying 
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sometimes found in CVS patients (Hejazi & McCallum, 2011). In a recent study 
investigating ghrelin levels in 22 adult CVS patients, it was found that the serum ghrelin 
levels were significantly higher than the control population (Hejazi et al., n.d.). These 
elevated ghrelin level findings could possibly contribute to the pathophysiology of CVS.  
Gastric Emptying Time  
Abnormal gastric emptying time has been observed in CVS patients and is 
theorized to play a role in the pathophysiology. The group that investigated ghrelin levels 
in CVS, Hejazi et al. looked at GET in adult CVS patients. Of 92 adults, they found 59% 
of subjects had rapid GET, 27% normal and 14% delayed during the inter-episodic period 
when they were asymptomatic (Hejazi, Lavenbarg, & Mccallum, 2010). They proposed 
that the abnormal hormonal finding suggests a possible mechanism of ghrelin facilitating 
the rapid GET they found in the majority of CVS patients. Furthermore, in the few 
studies that could be performed during the vomiting phase, there was a delay in GET 
(Hejazi, Lavenbarg, & Mccallum, 2010). An explanation for this may lie in CRF and it’s 
downstream effectors, cortisol and prostaglandin E2 being inhibitors of gastric empting 
(GE) (Hejazi & McCallum, 2011). These abnormal findings in GE could possibly point 
to an underlying autonomic dysfunction in CVS patients (Hejazi, Lavenbarg, & 
Mccallum, 2010). 
Autonomic Nervous System Dysfunction 
 The autonomic nervous system is involved with the generation of the emetic 
response. Via vagal and sympathetic afferent nerves, the brainstem nuclei receives the 
emetic signal and efferent responses are generated which subsequently causes the muscle 
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coordination involved with vomiting (Abell et al., 2008). Testing done on the autonomic 
nervous system (ANS) in CVS patients have revealed dysautonomia. In a study of 22 
adults, 9 patients had autonomic nerve abnormalities with a dominance of sympathetic 
dysfunction over parasympathetic (Hejazi et al., 2011).  This finding is consistent with 
three reports of increases in sympathetic tone in pediatric CVS patients (Hejazi & 
McCallum, 2011). CVS patients with these abnormalities maybe vulnerable to an over 
response to emetic signaling (Abell et al., 2008). 
Mitochondrial DNA Polymorphisms 
Studies that have looked at family medical history and co-morbid conditions in 
CVS patients have alluded to mitochondrial DNA (mtDNA) defects contributing to the 
disorder. mtDNA is inherited exclusively from the maternal line and the 37 genes are 
involved in energy metabolism (Abell et al., 2008).  It is theorized that dysfunction of the 
mitochondria may contribute to autonomic nervous system dysfunction in CVS patients 
and render individuals susceptible to vomiting episodes during periods of high energy 
demands such as periods of stress and illness (Abell et al., 2008). Supporting this theory 
is the observation in families where more than one member has been affected by CVS, 
that there is a predominantly maternal inheritance pattern (Pareek et al., 2007).  
Furthermore, dysautonomic and functional disorders often found co-morbid in 
CVS patients, specifically migraine, show a maternal inheritance pattern as well (Abell et 
al., 2008). A group that sequenced the entire mtDNA genome in 20 CVS patients as well 
as 10 subjects selected for specific mtDNA polymorphisms found the single nucleotide 
polymorphisms (SNPs) 16519T and 3010A strongly associated with both CVS and 
	  	   5	   	  	  
migraine without aura and were likely to render individuals susceptible to these diseases 
(Zaki et al., 2009). Another study found that adult onset CVS was not correlated with the 
SNPs 16519T and 3010A and these polymorphisms were restricted to pediatric onset 
CVS only (Boles et al., 2009). This suggest that while these two migraine mtDNA 
polymorphisms may play a role in the development of CVS in children, there maybe 
other defects in energy metabolisms in adult onset CVS that render adult and pediatric 
CVS genetically distinct, however further investigation is needed into this matter (Boles 
et al., 2009).  
Associated Conditions 
 Migraines, psychiatric illnesses, chronic marijuana use, gastro-esophageal reflux 
disease, irritable bowel syndrome (IBS) and diabetes mellitus are all conditions found to 
be associated with CVS (Hejazi & McCallum, 2011). The association between migraine 
and CVS has been noted in the literature for some time. It is estimated that migraines are 
found in or there is a family history of migraines in 39-82% of children and 24-70% of 
adults with CVS (Hejazi & McCallum, 2011). This association maybe due to more 
generalized abnormalities of the central nervous system (Abell et al., 2008). Diabetes is 
also noted at higher prevalence in CVS syndrome than the general population. One study 
found that in their cohort of patients, 13% had diabetes mellitus (Hejazi, Lavenbarg, & 
Mccallum, 2010). In addition, IBS was noted in up to 67% of CVS patients and seizure 
disorder in up to 5.6% of patients as compared with 10-20% and .5-1% respectively of 
the general population (Pareek et al., 2007). 
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 Psychiatric illness has also been well documented in patients with a high 
preponderance of anxiety and depression disorders. In a study of pediatric CVS patients, 
one group found that 15% of preschoolers, 59% of school children and 54% of 
adolescents met the criteria for an anxiety disorder (Tarbell & Li, 2008). In adults, 
Fleisher et al. found anxiety, mood disorder, alcohol and/or drug abuse in 70% of patients 
(Fleisher, Gornowicz, Adams, Burch, & Feldman, 2005). Namin et al. reported up to 84% 
of adult patients suffering from an anxiety disorder and 78% from depression (Namin et 
al., 2007) It is unclear if depression and anxiety contribute to the onset of CVS or if they 
are manifestations of the nature of the disorder itself. However half of patients reported 
mental stress as contributory to the onset of an episode (Namin et al., 2007). In addition, 
Fleisher et al. also found 17% of adult patients attributing anticipatory anxiety as a trigger 
to episode onset and 68% of patients noted panic attack symptoms when the felt an 
episode coming on and during the vomiting phase (Fleisher et al., 2005).  
CVS Phases  
The nature of CVS is such that it can be divided up into 4 stereotypic phases. 
1. Prodromal: This phase is usually of sudden onset and the patient senses the 
episode coming on. This phase usually lasts anywhere from 1-2 hours and the 
patient may have abdominal pain, pallor, lethargy, and anorexia (Tonore et al., 
2013). 
2. Emetic phase: The patient is actively vomiting, is persistently nauseous and is 
unable to keep down fluids or medication. Abdominal pain, listlessness and 
	  	   7	   	  	  
dehydration is frequent and this phase can last anywhere from hours to days 
(Abell et al., 2008).  
3. Recovery phase: This phase begins when nausea and vomiting have ceased and 
the patient is able to resume oral intake (Abell et al., 2008). 
4. Inter-episodic period: This phase can last anywhere from weeks to months and is 
a period of wellness where the patient does not experience nausea or vomiting 
(Abell et al., 2008) 
The age of onset of the first episode has been reported to be anywhere from 6 
days to 73 years old (Tonore et al., 2013). Additionally patients have reported that there 
will be events that trigger episode onset. Most common triggers include illness, physical 
and psychological stress including birthdays, vacations, lack of sleep, change of season, 
certain foods, and in females the onset of a period (Pareek et al., 2007). Often, during the 
prodromal phase, patients seek out dark and quiet rooms void of stimulation (Pareek et 
al., 2007). Episode onset frequently begins for many patients between the hours of 2:00 
am and 7:00 am (Tonore et al., 2013). Once an episode has begun patients have been 
known to seek relief in unusual ways. Taking long hot showers or baths as well as a 
“guzzle and vomit” action where the patient ingests large amounts of liquid to induce 
vomiting has been noted (Pareek et al., 2007).  
CVS adult vs. child 
 Age of symptom onset in adults is reported to be on average 35 years with 
diagnosis at 41 years (Tonore et al., 2013). In children symptom onset is on average 5.3 
years old and diagnosis 9.6 years (Tonore et al., 2013). Adult patients on average had a 
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frequency of episodes similar to childhood onset with 1.2 episodes/month and .8 
episodes/month respectively, however adults experienced a longer duration of episodes, 
5.9 days compared to pediatric patients, 3.4 days (L. Y. W. Lee, Abbott, Mahlangu, 
Moodie, & Anderson, 2012). Although it has been suggested that adult CVS is more 
severe, studies between pediatric and adult cohorts have shown to be variable throughout 
the literature. Lee et al. showed that in the study’s cohort of patients, childhood onset was 
more severe with 15 more attacks/year than children (25/year vs. 10/year) (L. Y. Lee, 
Abbott, Moodie, & Anderson, 2012). Another group, found that pediatric patients had a 
higher incidence of CVS plus a neurocognitive disorder and a longer delay in diagnosis 
as compared to adults (Kumar et al., 2012).  In contrast to this Boles et al. found that 
adult onset was more strongly associated with functional disorders and dysautonomous 
conditions such as migraine (Boles et al., 2009). It is thought that migraine headaches 
occur more frequently in adult patients with CVS, with a prevalence of 24-70% in adults 
and 39-82% in children (Abell et al., 2008). In addition, in some children there maybe the 
loss of CVS vomiting features and the development of migraines when the child reaches 
adolescents (Abell et al., 2008). The variability of characteristics in CVS patients both 
adult and pediatric provides the necessity for further investigation into patient profiles.  
Diagnosis 
Historically, vomiting that was of unknown causes was frequently labeled as 
psychogenic (Talley, 2007). Now, diagnosis of CVS is based on Rome III Criteria for 
Functional Gastrointestinal Disorders and is in the same category as similar vomiting 
disorders such as chronic idiopathic nausea, functional vomiting and rumination 
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syndrome (Drossman). In order for a patient to receive a diagnosis of CVS all of the 
following conditions must be met. 
1. Acute vomiting onset lasting less than one week. 
2. Three or more episodes in the last year 
3. Wellness between episodes (no nausea or vomiting).  
 Criteria supporting a diagnosis are a family history or patient history of migraines 
(Drossman). As there are several disorders that show similarities to CVS, it is important 
to rule out others before arriving at a diagnosis.  
Table 1: Differential Diagnosis 
Non-surgical Gastrointestinal Disorders Peptic ulcer disease, hepatitis, pancreatitis 
with or without pseudo cyst, motility 
disorders, inflammatory bowel disease, 
infections 
Surgical Gastrointestinal Disorders Pancreatic pseudo cyst, recurrent sub acute 
appendicitis, bowel obstruction, 
intermittent duodenal intussusception, 
duodenal web/atresia/diverticulum, 
adhesions, choledochal cyst, 
cholelithiasis/gallbladder dyskinesia, 
gastrointestinal malignancies 
Urologic/Renal/Gynecologic Disorders Urolithiasis, reteropelvic junction 
obstruction, ovarian cyst, pregnancy, 
premenstrual syndrome 
Neurological Disorders Hydrocephalus/slit ventricle syndrome, 
brain tumors, budd chiari malformations, 
epilepsy, subdural hematomas or effusions, 
familial dysautonomia 
Endocrinologic disorders Diabetes mellitus, adrenal insufficiency, 
pheochromocytoma 
Miscellaneous disorders Abdominal migraines/epilepsy, 
hypothalamic surge, asthma, chronic 
sinusitis, benign positional vertigo, 
psychiatric disorders 
(Modified from Pareek et al., 2007) 
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Diagnostic Tests 
 Although there are no tests specifically for CVS, there are several exams to run in 
order to exclude other causes of nausea and vomiting (Hejazi & McCallum, 2011). Upper 
endoscopy, small bowel X-ray, CT scan, gastric emptying time study, biochemical 
analysis for electrolyte imbalances, liver chemistry, pregnancy tests, pancreatic enzyme 
testing and hormonal testing maybe helpful when deciding upon a CVS diagnosis (Hejazi 
& McCallum, 2011; Talley, 2007)  
Difficulties in Diagnosis and Recognition  
 Lack of recognition of CVS by physicians often leads to misdiagnosis and 
suboptimal care in patients, affecting an individual’s quality of life and ability to manage 
the disease. There is typically a delay of 3-8 years in the adult population and a 2.5 year 
delay in the pediatric population (Venkatesan et al., 2010). As patients often utilize the 
emergency department (ED) during attacks it is important that emergency physicians 
recognize the disorder and the patient receives a diagnosis if they have not already had 
one. However, in the ED it is not uncommon for patients to receive a diagnosis of viral 
gastroenteritis or food poisoning (Abell et al., 2008). Based on a survey of CVS patients, 
it was found that in 80% of CVS patients, the disorder was not recognized both before 
and after diagnosis (Venkatesan et al., 2010). The majority of patients in this study were 
not recommended to be seen by a gastroenterologist as well (Venkatesan et al., 2010).  
 Physicians’ inability to diagnosis CVS results in unnecessary procedures and tests 
performed on patients as well. In a study of 41 patients, it was found that 16 patients 
underwent surgical attempts to correct CVS with none finding improvement in their 
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symptoms (Fleisher et al., 2005). Lack of recognition and referral to specialists greatly 
impacts a patient’s ability to receive appropriate prophylactic care. This can result in 
financial burdens and a poor quality of life as employment, education, family and social 
environment are all affected by this disorder. 
Treatments 
To treat CVS, physicians have typically recommended both pharmacological 
interventions and lifestyle changes. Figure 1 represents the treatment goals of each phase. 
There are measures that can be taken as prophylactic therapy to prevent episodes, 
abortive therapy during the prodromal phases, and treatment to keep the patient hydrated 
and lessen the severity of the emetic phase and recovery phase. 
 
Figure 1. Cyclic Vomiting Syndrome Phases and Treatments Goals. CVS phases and 
treatment goals schematic (Figure taken from Fleisher et al., 2005) 
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Inter-episodic Period Therapy 
 Important lifestyle changes should be implemented with CVS patients. Patients 
should learn to recognize triggers and if possible avoid them as well as get adequate 
amounts of sleep. In addition, behavioral therapy and biofeedback may prove beneficial 
to some patients. In a case report of a 13 year old boy with CVS the psychotherapist 
aimed to reduce anticipatory anxiety and to address the theory of underlying autonomic 
nervous system dysfunction in CVS patients through biofeedback (Slutsker, Konichezky, 
& Gothelf, 2010). Gaining insight into his trigger factors, learning stress reduction, 
relaxation and biofeedback techniques the patient remained symptom free throughout the 
4 month treatment and at a 4 month follow-up (Slutsker et al., 2010). 
 Pharmacologically, several studies have proven tricyclic anti-depressants (TCAs) 
to be an effective treatment option. It is theorized that TCAs could possibly be affecting 
the central nervous system, modifying the brain-gut axis and underlying autonomic 
dysfunction found in some patients (Hejazi, Reddymasu, et al., 2010). As TCAs have also 
been shown to inhibit the CRF gene promoter region, it is possible that TCAs are 
alleviating symptoms through down-regulation of CRF (Hejazi & McCallum, 2011). In a 
two-year study with 46 patients, 88% of patients saw a significant reduction in the 
frequency and duration of episodes, as well as the number of ED visits and 
hospitalizations as compared to baseline status (Hejazi, Reddymasu, et al., 2010). In 
addition, 3 patients in the study had complete resolution of symptoms (Hejazi, 
Reddymasu, et al., 2010). 
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Non-steroidal anti-inflammatory (NSAID) proved effective for one adult male in 
a case report study. The patient, diagnosed with CVS and experiencing symptoms on a 
weekly basis was prescribed meloxicam, an NSAID for his back pain. When on a full 
dose of meloxicam (15 mg) and a small dose of a TCA, the patient experienced full 
resolution of CVS symptoms (Vidula, Wadhwani, Roberts, & Berkowitz, 2013). The 
authors of this paper proposed that CVS episodes were terminated in this patient through 
the known mechanism of NSAIDs inhibition prostaglandin synthesis, which normally 
stimulates ACTH release and initiates vomiting (Vidula et al., 2013). This inhibition 
maybe the cause of the cessation of vomiting the patient experienced and could serve as a 
useful treatment regime along with TCAs for other CVS patients. 
Additional medications addressing conditions associated with CVS maybe 
beneficial to patients. For those patients who experience migraines it is recommend that 
in children β-receptor antagonists and histamine (H1)/serotonin receptor antagonists such 
as propranolol and cyproheptadine be added to a TCA regime (Hejazi & McCallum, 
2011). In adults, TCAs and topiramate is recommended for those who experience 
migraine (Hejazi & McCallum, 2011). In addition, benzodiazepines for anxiety disorders, 
antispasmodic agents for IBS, anti-emetic agents for nausea that may occur between 
episodes, proton-pump inhibitors for gastro-esophageal reflux, and non-narcotic pain 
relievers for those that experience significant abdominal pain as well as seeking out 
treatment from a pain specialist should be incorporated into a CVS regime for those 
affected by additional conditions (Abell et al., 2008). 
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Abortive and Acute Phase Treatments 
During the prodromal phase, some physicians have recommended NSAIDs, 
drinking sweet caffeinated drinks, intravenous or oral dexterous and the use of anti-
migraine agents such as 5HT1B/1D receptor agonists (Abell et al., 2008). The hope of 
administration of these agents is to either abort or lessen the severity of the episode 
through very early treatment. During the vomiting phase, patients often find that they 
require hospitalization or treatment in the ED for dehydration. It is recommended that 
patients receive a 5-10% dextrose solution for intravenous fluid replacement as this 
hydration regime appears to be of greater therapeutic efficacy in CVS patients (Abell et 
al., 2008; Hejazi & McCallum, 2011). Intravenous anti-emetic agents administered at 
high doses, sedatives, and narcotics are all useful in helping patients experience symptom 
relief (Hejazi & McCallum, 2011). Additionally, as CVS is often not recognized in the 
ED, where patients receive emetic phase relief it can be helpful for patients to carry a 
protocol of treatment. It was found that of those patients that who had protocols, 80% had 
their protocol followed by ED physicians (Venkatesan et al., 2010).  
CVS and Marijuana  
Cannabinoid Hyperemesis Syndrome 
Cannabis use has often been found at higher frequency of usage among Cyclic 
Vomiting Syndrome patients. The role of cannabis as a contributory or ameliorating 
factor to CVS has yet to be determined. However, when diagnosing and treating CVS 
patients who engage in cannabis use, it important to distinguish CVS from another 
disorder that shows striking similarities, Cannabinoid Hyperemesis Syndrome (CHS). 
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According to case reports, patients with CHS tend to be heavy cannabis users with daily 
use often reported, their vomiting begins after engaging in marijuana use, they frequently 
take hot showers to alleviate symptoms, abdominal pain accompanies episodes, and 
cessation of vomiting is observed after discontinuation of marijuana use (Donnino, 
Cocchi, Miller, & Fisher, 2011; Sontineni, 2009). In addition, many patients have been 
heavy cannabis users for years before episodic vomiting begins (Sullivan, 2010).  Like 
CVS, there are three stereotypical phases to the disorder. The prodromal phase starts with 
nausea and stomach pain in the early morning however, the patient can still engage in 
oral intake of food and liquids (Galli, Sawaya, & Friedenberg, 2011). The vomiting phase 
of CHS is very much like CVS in that vomiting is profuse and frequent. During the 
recovery phase, oral intake is able to be resumed and normal health is returned however 
this may take days, weeks or months (Galli et al., 2011). Often, confusion exists in 
diagnosing patients who use cannabis and have CVS and those whose cannabis use are 
causing CHS. Similarities between the two syndromes include the presence of a 
stereotypical prodromal, vomiting and recovery phase as well as a hot shower or bathing 
phenomenon to alleviate symptoms. In addition, there is often a high prevalence of 
marijuana use in the CVS population to alleviate inter-episodic nausea and vomiting. 
However, there are several important distinguishing factors between the two syndromes 
that should be taken into account when diagnosing and differentiating the two vomiting 
disorders. Table 2 helps to differentiate CVS vs. CHS and highlights important 
differences. Important characteristics to note are the presence of occasional to frequent 
cannabis use in CVS patients but not universal use in CVS patients where as all CHS 
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patients use cannabis. The cessation of cannabis use may help to ameliorate frequency of 
symptom development in some CVS patients but not necessarily all CVS patients as 
some have noted marijuana to help their nausea and vomiting. In the case of CHS, 
cessation of cannabis completely stops symptom development where as CVS patient’s 
still experience symptoms even with cannabis cessation. There is often a strong family or 
personal history of migraine in CVS patients with a migraine like aura sometimes 
accompanying vomiting episodes where no migraine exists in CHS patients. Gastric 
emptying time in CVS patients often tends to be accelerated where in CHS patients, GET 
is delayed due to the effect of cannabis on the gastrointestinal system.  
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Table 2. Cyclic Vomiting Syndrome vs. Cannabinoid Hyperemesis Syndrome. A 
table highlighting the differences between CVS and CHS (Figure adapted from Galli et 
al.) 
 
 Cyclic 
Vomiting 
Syndrome 
Cannabinoid Hyperemesis 
Syndrome 
Age of Diagnosis (y) 34.8 29.3 
Delay in Diagnosis 
(y) 
7.9 3.1 
Duration of episodes 
(days) 
3.8 N/A 
Cannabis Use Occasionally to 
Frequent 
Universal 
Triggers Frequent Absent 
Prodrome Common Common 
Vomiting Universal Universal 
Abdominal Pain Common Common 
Compulsive 
Bathing/Showering 
Occasional Occasional 
GET Accelerated Delayed 
Comorbidities 
Psychiatric 
Conditions 
Common Not common 
Migraine Headaches Common 
(24-70%) 
Not common 
Treatment Anti-migraine 
agents, TCA, 
trigger 
avoidance 
Cannabis cessation 
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Cannabis and CVS 
 Studies that have taken note of cannabis use in CVS patients have yet to elicit a 
relationship between use and symptoms. However a high prevalence of marijuana use in 
CVS patients have lead to some investigators reporting on descriptive characteristics of 
CVS patients who use marijuana. In a literature review of CVS adults, it was found that 
42-53% of CVS patients used marijuana and that substance use often predated CVS 
episodes by 5-10 years (Pattathan, Hejazi, & McCallum, 2012). Furthermore, one group 
found that cannabinoid use in specifically the male gender was more strongly associated 
with CVS as compared with functional vomiting (Choung et al., 2012). When looking at 
treatments typically recommended for CVS patients, Hejazi et al. found that those 
patients with chronic marijuana use, migraine headaches, psychological illnesses or 
dependence on narcotics for pain control were more likely to not respond to TCA 
treatment (Hejazi, Lavenbarg, Foran, & McCallum, 2010). However, patients that were 
chronic marijuana users viewed marijuana as a beneficial agent initially in their treatment 
regime but some individuals saw a lessening of therapeutic effect after years of use 
(Hejazi, Lavenbarg, Foran, et al., 2010).  
 In studies on GET in CVS patients, there have been mixed reports on the effect of 
marijuana use on GET as well. In one study conducted by Hejazi et al. they found that 
there was a slow GE in observed in 14% of CVS patients studied and of those, there was 
more likely to be chronic marijuana and chronic narcotic use (Hejazi, Lavenbarg, & 
Mccallum, 2010). The same group in the study looking at non-responders to TCAs 
however observed that there was no difference in GET among those that responded to 
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treatment and the non-responders (marijuana and narcotic users, psychiatric disorders, 
migraine headaches) (Hejazi, Lavenbarg, Foran, et al., 2010).   
 Recording patient views on their own marijuana use, Kumar et al. observed that a 
third of their CVS patients used marijuana as a remedy for nausea and to stimulate 
appetite and the authors believed that there was no connection between marijuana use and 
symptom onset (Kumar et al., 2012). In another study, Namin et al. found 13 (42%) 
patients in his study group used marijuana daily to weekly and out of the 13, 7 viewed 
marijuana as beneficial to their symptoms, 4 with no regards to marijuana use and their 
symptoms and 2 with observed symptom improvement upon cessation of use (Namin et 
al., 2007).  
 The lack of consensus on the role of marijuana in the CVS population calls for 
additional investigation into the possible benefits and harmful outcomes of cannabis use 
among CVS patients. However, the historically and generally conservative views among 
physicians towards marijuana’s therapeutic effects may hinder or bias investigation. In a 
study done looking into physician views of medical marijuana among a study cohort of 
Colorado based physicians, more than 60% of participants thought there were significant 
risks both mentally and physically to marijuana use with only 27% viewing marijuana as 
having significant therapeutic value (Peckham, Stetka, & Vega, n.d.). The role of 
marijuana use in the CVS population needs to be further examined as well as additional 
characterization of both the disease and patients suffering from this poorly understood 
disorder.  
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 In summary, due to the nature and rarity of CVS, this disease is difficult to 
investigate and remains poorly understood. We have reviewed the literature and have 
identified several gaps requiring further investigation. Additional insight is needed into 
what population is affected in terms of age, race and gender; the health care utilization by 
CVS patients; a deeper characterization of the patient profile in terms of associated 
conditions and the prevalence of substance abuse; and patients treatment regimes both 
traditional pharmacological methods as well as non-traditional methods patients may use 
to self medicated such as marijuana. Of possible areas, we specifically aim to 
characterize patient’s demographics, disease co-morbidities, ED utilization, predictors of 
marijuana use in CVS patients, and effect of marijuana in determining health care 
utilization in order to further contribute insight into the syndrome.
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METHODS 
We chose to further describe CVS patients and predictors of marijuana use 
through a retrospective patient chart review of individuals seen at Massachusetts General 
Hospital (MGH). Using a Partners Health Care System/MGH specific research tool, 
Research Patient Data Registry (RPDR), we used a query search to obtain a total of 640 
patients. We then carefully analyzed the electronic medical records of the 640 patients 
excluding those patients with a history of hyperemesis gravidarum, chronic idiopathic 
nausea and vomiting, eating disorders, and CVS mentioned only in the differential 
diagnosis. We were able to obtain a total of 91 patients who received a diagnosis of CVS 
in their medical record, whose diagnosis was further verified based on the clinical 
expertise of one of the authors and through meeting Rome III criteria. Additionally, those 
selected were seen as either an inpatient, outpatient or in the ED at MGH over a 16 year 
period (1997-2013). Initially, of these 91 CVS patients, we collected data on the variables 
in Table 3 
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Table 3: Variables collected on 86 CVS patients seen at MGH between 1997-2013 
Demographics: • Sex 
• Race 
• Ethnicity 
• Employment status 
• Education level 
• Zip code 
Patient Medical History: • Height 
• Weight 
• Body Mass Index (BMI) 
• Age of First CVS attack 
• Presence of diabetes and mitochondrial 
disease  
• Gastroenterology (GI), psychiatric and 
neurological diagnoses. 
Health Care Utilization: • Number of ED visits 
• ED chief complaint 
• Number of admissions 
• Presence of a GI or Psychiatric consult upon 
admission 
• Length of stay upon admission 
• Number of outpatient visits for a GI doctor 
• Time span going to a GI doctor 
• Number of outpatient for primary care doctor, 
psychiatric, pain management specialist, 
neurology, immunology and urgent care 
• Their total time span of contact at MGH 
Substance abuse history and frequency of use: • Alcohol 
• Tobacco 
• Marijuana 
• Narcotics 
• Cocaine 
• Heroine 
• Benzodiazepines 
• Ecstasy 
Prescription Medication: • Presence of a dronabinol prescription 
• Purpose of dronabinol prescription 
• Self reported dronabinol efficacy 
• Length of dronabinol prescription 
• Number of ED visits 6 months before and 
after dronabinol 
• Active and Inactive medications 
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Of these variables, we used descriptive statistics to describe our cohort’s gender, 
employment, age of first attack, psychiatric conditions, marijuana use, alcohol use, 
narcotic use, chronic pain syndromes, and ED usage. Using Statistical Analysis Software 
(SAS) we first performed univariate analysis to examine differences in CVS patient 
marijuana users vs. CVS patients non-marijuana users. Fischers exact test was used for 
dichotomous variables and T-test was used for continuous variables. In addition we used 
SAS multivariate analysis logistic regression controlling for the variables alcohol use, 
age, sex, psychological diagnosis, narcotic use and chronic pain to determine the 
variables that were predictors of marijuana use in our CVS population. Of the categories, 
we chose to exclude the data with incomplete information from our descriptive, 
univariate and multivariate analysis. 
 
 
 
 
 
 
 
 
 
 
 
	  	   24	   	  	  
 
RESULTS 
Characterization of Cohort 	  
As seen in Table 4 which highlights our results on the descriptive statistics of our 
cohort, of the 91 patients, there were 57 males (67%) with a mean age of 28 years, 
average age of first attack of 20.2 years and an employment rate of 62% of our cohort 
being either employed or full time students. 
73% of the cohort had a psychiatric condition with anxiety (50%) predominating 
followed closely by depression (47%). The other co-morbid condition we analyzed was 
the presence of a chronic pain syndrome, which we defined as lower back pain, migraine 
headaches and fibromyalgia. A chronic pain syndrome was found in 40% of our cohort. 
History of substance use or abuse was found in a significant number of patients. 76% of 
our cohort had a history of THC exposure, which we defined as marijuana use or 
dronabinol prescription. In addition 51% used alcohol daily, and 28% were found to be 
regular users of narcotics, both heroine and pill form. 
ED usage by patients was found to have an occurrence on average of 1.6 times per 
year. In our cohort, all patients were found to have presented to the ED at least once a 
year with one patient having a very high 208 ED visits in one year. Of patients who 
presented more than once during the total duration of the years in study (1997-2013), 
there was a median interval between ED visits of 103.6 days. ED chief complaint 
included abdominal pain, nausea and vomiting which was present in 82% of patients. 
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Univariate Results 
We first used univariate analysis to screen for significant variables associated 
with marijuana use in our CVS population. Table 5 highlights our findings. Of interest 
sex (p-value .0246), chronic pain (p-value .0351), and education level (p-value .0328) 
were found to be variables of significance.  
Multivariate Results 
From univariate analysis, we used multivariate logistic regression analysis in SAS 
and found daily alcohol use to be associated significantly with marijuana use in our CVS 
population (OR 5.26, 95% CI 1.469-18.828). Men were also significantly more likely to 
use marijuana than females (OR .23, 95% CI .07-.77). Interestingly, the presence of a 
chronic pain syndrome significantly lowered the risk for cannabis use (OR .15, 95% CI 
.039-.575). Of the other variables we examined in the multivariate logistic regression, the 
presence of a psychiatric illness, patient age and narcotic use were not significantly 
associated with marijuana use. 
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Table 4: Results Summary 
Gender: 
Male: 
Female: 
 
67% 
33% 
Age: 
Mean age 
Age of first attack  
 
28 years 
20.2 years 
Employment: 67% 
Psychiatric Illness: 
Depression 
Anxiety 
 
47% 
50% 
Chronic Pain Syndrome: 40% 
Substance Abuse: 
Marijuana: 
Alcohol: 
Narcotics: 
 
67% 
51% 
28% 
ED Use: 
Average: 
Interval between visits:  
 
1.6 time/year 
103.6 days 
 
Table 5: Univariate Analysis of Predictors of Marijuana Use 
*Denotes variables of significance  
Variables Non-
Marijuana 
Users 
Marijuan
a Users  
Fischer’s 
Exact Two 
sided P value 
Relative 
Risk 
Value 
95% confidence 
interval 
T 
value 
Sex*   .0246 .4540 .2366, .8710  
Male 12 (13.19%) 49 
(53.85%) 
    
Female 13 (14.29%) 17 
(18.68%) 
    
Race   .1220    
White 20 (22.73%) 54 
(61.36%) 
    
Black 1 (1.14%) 2 (2.27%)     
Hispanic 0  6 (6.82%)     
Asian 3 (3.41%) 1 (1.14%)     
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Other 0 1 (1.14%)     
BMI x=24.0818 x=25.5315    .1286 
Age of first 
attack 
x=19.2528 x=20.5215    .5705 
Marital Status   1.0 1.0811 .4276, 2.7334  
Single 20 (22.22%) 54 (60%)     
Married 4 (4.44%) 23 
(13.33%) 
    
Employment   1.0 1.0667 .5176, 2.1982  
 
Unemployed 
12 (14.12%) 33 
(38.82%) 
    
Employed 10 (11.76%) 30 
(35.29%) 
    
Education* 
Level  
  .0328    
Nothing 8 (10.38%) 14 
(18.18%) 
    
High School 5 (6.49%) 8 
(10.39%) 
    
College 5 (6.49%) 37 
(48.05%) 
    
TCA 
prescriptions 
  .4360 1.4545 .6146, 3.4423  
No TCA 20 (22.22%) 46 
(51.11%) 
    
TCA 5 (5.56%) 19 
(21.11%) 
    
Psych 
Diagnosis 
  .6030 1.2424 .6151, 2.5094  
No Diagnosis 8 (8.79%) 17 
(18.68%) 
    
Diagnosis 17 (18.68%) 49 
(53.85%) 
    
Chronic Pain*   .0351 .4780 .2414, .9465  
No Pain 10 (10.99%) 43 
(47.25%) 
    
Pain 15 (16.48%) 23 
(25.27%)  
    
Anxiety   .1658 1.6643 .8218, 3.3703  
No Anxiety 16 (17.58%) 31 
(34.07%) 
    
Anxiety 9 (9.89%) 35 
(38.46%) 
    
Depression   .8147 .8642 .4430, 1.6858  
No Depression 12 (13.19%) 35 
(38.46%) 
    
Depression 13 (14.29%) 31 
(34.07%) 
    
Narcotic Use   .1047 2.4804 .8176, 7.5247  
	  	   28	   	  	  
 
  
  
No Narcotics 22 (24.18%) 46 
(50.55%) 
    
Narcotics 3 (3.30%) 20 
(21.98%) 
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 DISCUSSION 
 Our study compiled the experience of CVS patients seen at a tertiary care center 
over the span of 13 years. Through retrospective patient chart review we described our 
cohort based on demographics, co-morbidities, substance abuse history, and ED usage. In 
univariate analysis sex, educational level and chronic pain were shown to be variables 
that showed a statistical difference between CVS marijuana users and non-users. Upon 
multivariate analysis controlling for the variables of alcohol use, age, sex, psychological 
diagnosis, narcotic use and chronic pain, we found sex, alcohol use and chronic pain to be 
predictors of marijuana use in CVS patients. Our samples size of 91 patients is fairly 
large in comparison to other CVS studies and our result differ from the literature in terms 
of employment status, presence of chronic pain, emergency department use, and 
substance abuse.  
As CVS has been historically thought of as a disorder of pediatric patients, there 
now is an increasing investigation into adult CVS. The higher average age of our CVS 
population and age of first attack in our CVS cohort represents an older demographic of 
CVS patients rather than the traditional study of a pediatric group. As seen in Table 6, our 
average age and age of first attack is comparable to other recent studies but appears to be 
a bit more male skewed than other groups. 
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Table 6: A Comparison of Demographics 
  Choung et al. Namin et al. Lee et al. Hejazi et al. 
Total (n) 91 30 31 29 92 
Average 
Age 
28 years 30 years 29 years 28 years 37 years 
Age of 
First Attack 
20.2 years - 30 years 21.1 years 22 years 
Gender 
Breakdown 
67% male 67% male 58% male 35.7% male 51% male 
 
 The high employment and full time student status of our cohort represents perhaps 
a higher degree of functionality within our population. This is perhaps due to the location 
of our center. Boston has many medical resources in comparison to other areas of the 
country. The ease of availability and accessibility to centers that have much experience 
with more rare and difficult to treat disorders like CVS could explain why our population 
enjoys a higher employment and full time student status. This finding is unique in that it 
has been frequently observed that individuals affected with CVS have significant 
impairments to employment and ability to attend school. One report found that 57% of 
non-responders to TCA treatment experienced both disability and loss of job and 20% of 
responders experienced disability and 31% loss of job (Kumar et al., 2012). In addition 
Fleisher et al. found that out of 39 patients, 17 (43.5%) had moderate CVS characterized 
as work or educational status being in jeopardy and 19 (48.7%) had severe CVS defined 
as the duration of time ill equaled or exceeded their duration of periods of wellness 
(Fleisher et al., 2005)	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 Although there are no specific prevalence rates documented for the co-morbidities 
we chose to analyze in CVS patients, the higher incidences of depression and anxiety 
found in our cohort is consistent with many studies findings of a mental illness diagnosis 
within the CVS population. A high incidence of psychiatric illnesses is not uncommon in 
CVS due to the nature of the disorder. Many patients experience anxiety and depression 
relating to their symptoms and the affect it has on their life. Anxiety is sometimes noted 
by patients as a precipitating factor to symptom development and many patients 
experience anxiety when thinking about their illness or events that commonly trigger an 
episode. Kumar et al. found a similar rate of anxiety and depression (47% and 49% 
respectively) in his population of adult CVS patients along with Boles et al. who found 
both anxiety and depression in 55% his CVS cohort (Boles et al., 2009; Kumar et al., 
2012). Other studies have found depression to range anywhere from 6%-78% and anxiety 
from 8%-84% (Hejazi & McCallum, 2011).  
 CVS is a chronic condition that often has pain associate with it. Inter-episodic 
abdominal pain is sometimes noted in patients and many experience abdominal pain 
during episodes. In our cohort, 82% of patients experienced abdominal pain that 
accompanied nausea and vomiting. In addition to abdominal pain, 40% of our cohort was 
found to have a chronic pain syndrome. In the literature, pain is often recorded in the 
CVS population through the incidence of migraines and/or family history of migraines as 
the association of CVS and migraines has been well known for some time.	  One study 
done by Namin et al. even went so far as to specifically assess for pain using a visual 
analog scale (VAS) at baseline and after starting a treatment regime of amitriptyline 
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(Namin et al., 2007). However, we chose not to focus only on migraine in our analysis 
but more broadly the presence of a chronic pain syndrome due to the observation that 
individuals with functional disorders such as CVS often have other co-morbid functional 
pain disorders. In patients with IBS, a study found that there was a high prevalence of 
other functional pain disorders such as temporomandibular joint disorder and 
fibromyalgia (Kim & Chang, 2012). Furthermore, individuals with many co-morbid 
functional disorders have found to have central sensitization correlated with heightened 
pain perception (Kim & Chang, 2012). As pain syndromes have been analyzed in other 
functional GI disorders such as IBS, our documentation of the prevalence of chronic pain 
syndromes specific to the CVS population is the first. 
 As seen in Table 7, the frequency of emergency department usage by our patients 
of 1.6 times per year with a median interval of 103.5 days between visits is lower than 
other reports. In Kumar et al. study cohort, they recorded 3.4±9 ED visits/year of 
individuals who responded to TCA treatment and 15.8±9.2 of individuals who didn’t 
respond to TCA treatment (Kumar et al., 2012). Our ED visits per year is also lower than 
Hejazi et al. baseline measure of 15.8±13.4 visits per year before TCA treatment was 
initiated as well as the first and second years after TCA treatment (4.2±5 and 3.3±3.6 
visit per year respectively) (Hejazi, Lavenbarg, Foran, et al., 2010). 
 
 
 
 
	  	   33	   	  	  
Table 7: Comparison of ED Usage 
 . Kumar et al. Hejazi et al. 
ED usage/year 1.6 TCA responders: 3.4±9 
TCA non-responders: 
15.8±9.2 
Before TCA initiation: 
4.2±5 
After TCA initiation: 
3.3±3.6 
 
There are several reasons why our patients ED utilization maybe lower than 
others. It perhaps could represent a higher functionality by our patients where they have 
less health care utilization. This would coincide with our finding of a higher employment 
and full time student status in our cohort. In addition, over the past 5 years there have 
been an increasing number of patients with CVS being treated at MGH. Subsequently, 
the ED at MGH has become very knowledgeable about treating patients and giving 
patients protocols to control their symptoms to decrease hospitalizations. However, this 
finding was most likely due to our method of data collection. With retrospective data 
collection, we were only able to see patients that were seen at MGH without the ability to 
account for other visits at other health care facilities. It is however interesting that our ED 
utilization is lower than Kumar et al., who also gathered data through retrospective chart 
review of patients seen at their institution.  
 On a national level, the therapeutic use of marijuana for various disorders is 
increasingly being investigated. Since 1986, THC has been in use as an alternative to 
antiemetic drugs for individuals undergoing chemotherapy and as an agent to increase 
weight and appetite in those with conditions that cause cachexia such as HIV/AIDS and 
cancer (Peckham et al., n.d.). We chose to examine THC use in our cohort to further shed 
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light on marijuana use in the CVS population and to provide direction for additional 
studies as marijuana may prove to be a beneficial prophylactic treatment option for inter-
episodic nausea, appetite stimulant and perhaps method to reduce episode frequency and 
enhance quality of life. As shown in Table 8, our cohort has a very high marijuana 
prevalence rate in comparison to other groups.  
Table 8: Comparison of Substance Abuse 
  Hejazi et 
al. 
Lee et al. Choung et 
al. 
Namin et 
al. 
Hejazi 
et al. 
n 86 92 29 82 31  41 
Marijuana 
use 
76%  32%  17.4%  37% 42% 53% 
Narcotic 
use 
28% 19% - - - - 
Alcohol use 51% - - 28% - - 
 
 The very high marijuana use rate, low ED usage rate and high employment status 
may point to higher functionality and quality of life in our cohort due to marijuana use. 
Through multivariable regression we were not able to find a relationship between these 
variables due to small sample size and retrospective study design. Data on current and 
past marijuana use was often missing or difficult to determine in the medical history and 
an accurate capture of health care utilization was impossible as we could only see visits 
to our institution. Further investigation through prospective data collection would be a 
better tool to determine the role of significant marijuana use in a patient’s functionality 
and quality of life.  
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 Before multivariate analysis, univariate analysis was performed to see if there 
were any differences between non-marijuana users and marijuana users in terms of the 
variables collected in Table 4. We found sex, education level and chronic pain to be 
statistically significant differences between the two groups. There were more males in the 
marijuana user group, individuals with a college education were found at higher 
frequency in the marijuana users group and those with a chronic pain syndrome were less 
likely to use marijuana. The finding of more males using marijuana in comparison to 
females with CVS also proved to be true upon multivariate logistical regression and is 
consistent with prior literature. Generally, illicit drug use, including marijuana is more 
common in males than females (11.2% vs. 6.8%) for those age 12 and older (“Results 
from the 2010 NSDUH,” 2010). Specifically looking at CVS, it was found in a literature 
review that males were more likely to be marijuana users. A retrospective patient chart 
review study also revealed that cannabinoid use in males increased the odds for CVS (OR 
2.9, 95% CI 1.2, 7.2) (Choung et al., 2012; Pattathan et al., 2012).   
Education level and risk of marijuana use showed a surprising outcome in our 
cohort. It is generally presumed that a higher education level decreases risk of substance 
abuse. However, there seems to be a complex relationship between education level and 
substance abuse. According to a 2010 National Survey on Drug Use from the Department 
of Health and Human Services, there was an inverse correlation for the rate of illicit drug 
use and educational achievement with individuals not completing high school having the 
highest level of drug use and college graduates having the lowest risk of drug use 
(“Results from the 2010 NSDUH," 2010). When looking at lifetime rates of drug use 
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though, the opposite was found in that those with the lowest educational attainment had 
the lowest lifetime rate of drug use and those with the highest level of educational 
achievement had the highest rate (“Results from the 2010 NSDUH," 2010) .  
Looking specifically at marijuana use and education level, a twin study of 
Vietnam era veteran twins revealed that there were no differences in level of educational 
attainment in terms of marijuana use, early marijuana initiation and marijuana 
dependence (Grant et al., 2012).  In addition, some studies have found that those with a 
higher education were more disposed to use marijuana throughout the course of their life 
(Galea, et al.,2007). The more educated population having a higher risk of marijuana use 
in our cohort could reflect a higher level of disposable income that generally follows a 
greater educational attainment. In addition, marijuana maybe allowing the more educated 
CVS population to function better with their symptoms in comparison to the less 
educated CVS population.  
Our findings of the presence of a chronic pain syndrome lowering the risk of 
cannabis use in CVS patients in univariate analysis also proved to be of significance in 
multivariate logistical regression controlling for the variables of alcohol use, age, sex, 
psychological diagnosis, narcotic use and chronic pain. This goes against other findings 
of cannabis use in pain syndromes. Cannabis has been noted as treatment for chronic pain 
for thousands of years including neuropathic pain and fibromyalgia (Peckham et al., n.d.). 
A systematic review analyzing randomized controlled trials for the treatment of chronic 
pain with cannabis revealed cannabis had a modest effect on the treatment of chronic 
non-cancer pain with minimal to no side effects and should be consider a safe treatment 
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option for pain, particularly neuropathic pain (Lynch & Campbell, 2011). Given what is 
known about the use of marijuana in those with a chronic pain condition, it is surprising 
that individuals with CVS and a co-morbid pain condition were less likely to use 
marijuana. It maybe that individuals with a chronic pain condition in our cohort were 
abusing other, more dangerous forms of substances such as opioids. However we were 
unable to examine this due to difficulties in data collection. 
 Limitations 
 There are several limitations to our study. Being a retrospective design, we were 
only able to collect data that was present in the patient’s medical record and often had 
data that was not available. The variables that were particularly affected and difficult to 
collect were most recent height and weight, age of first CVS attack, education level, 
number of ED visits and admissions, the presence and type of a consult upon admission, 
type and frequency of outpatient admissions and substance abuse history. There was an 
average frequency of 7 individuals per variable with missing data in the univariate 
analysis with a range of 1-20 individuals. The variable with the lowest amount of missing 
data was BMI, the highest was education level and the second highest with a frequency of 
12, employment level. Many of these variables with data missing were key variable 
outcomes, which could have significantly affected our results and ability to achieve our 
initial objectives. To deal with this problem, we chose not to include individuals in 
analysis if there data was missing which could have biased analysis. In addition 
information on total frequency and type of health care utilization was difficult to gather 
due to only MGH records being available to our group. Some individuals only had one or 
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no recordings of ED visits at MGH with no mention of frequency of hospitalizations at 
other institutions in the medical record by physicians. Therefore our information was not 
an accurate reflection of our patient’s total medical usage and experience in every patient. 
Information such as the age of first CVS attack, most recent height, weight and substance 
abuse history was sometimes not documented as well. The lack of complete and accurate 
documentation on substance abuse history as well as the inability to see health care 
utilization at other institutions affected our ability to measure health care utilization 
frequency as an outcome of marijuana use to the point that we decided to only measure 
predictors of marijuana use in CVS patients. 
 Besides retrospective study design inherently limiting the information we could 
gather, MGH is a tertiary care center so patients seen here may not reflect the average 
CVS patient or the average CVS patient’s experience. We also did not have quality of life 
measures such as patient surveys to give patients to determine how marijuana use 
affected quality of life. The lack of control group also was a severe limitation on our 
study design. 
Future Directions 
 Future directions for our group would be to prospectively gather patient data 
through sending out quality of life surveys and surveys designed to record an individuals 
health care utilization to the patient’s home or e-mail address as well as collecting 
information on site through giving surveys to those our group personally treats at MGH. 
We will also have to select a control group to make future results more statistically sound 
and accurate description of CVS patients. In selection of a control group for the future, 
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we would try to select another functional disorder such as IBS, gastroparesis, or migraine 
and match them to our CVS cohort in terms of age, sex, and disease severity.  
Conclusion 
 We chose to examine a cohort of CVS patients at a tertiary care center in order to 
further describe this disorder and patient characteristics. In addition to analyzing patient 
demographics, co-morbidities and health care utilization, we originally hoped to see how 
marijuana use affected quality of life through the end point of ED usage. Due to the 
limitations of retrospective data collection, MGH being a tertiary care center and 
therefore not accurately reflecting the average CVS patient’s experience, lack of control 
group and lack of quality of life measures we instead described our cohort in terms of 
demographics, co-morbidities, ED utilization, substance abuse and variables that 
predicted marijuana use. We found a significant number of our patients had psychiatric 
conditions, chronic pain syndrome, and a history of substance abuse. In addition alcohol 
use and being male were two variables that predicted marijuana use in the CVS 
population while the presence of a chronic pain syndrome lowered the risk of marijuana 
use. The high employment status and marijuana use along with lower than average ED 
usage may point to a better quality of life due to marijuana use however further 
investigation is needed into this hypothesis. Future directions aim to conduct prospective 
trials including patient surveys, interviews and questionnaires conducted both in clinic 
and through mail measuring quality of life, health care utilization at MGH and outside 
hospitals, history of marijuana or dronabinol, and perceived patient benefit or detriment 
of marijuana to symptoms.	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